Eli Lilly and Company Forecast, price target & analysts
Eli Lilly and Company Target price 2025 - Analyst rating & recommendation
Eli Lilly and Company Classifications & Recommendation:
Eli Lilly and Company Price Target
| Target Price | $1,015.92 |
| Price | $1,010.31 |
| Potential |
0.56%
register free of charge
|
| Number of Estimates | 32 |
|
32 Analysts have issued a price target Eli Lilly and Company 2026 .
The average Eli Lilly and Company target price is $1,015.92.
This is
0.56%
register free of charge
$1,575.00
55.89%
register free of charge
$713.10
29.42%
register free of charge
|
|
| A rating was issued by 37 analysts: 28 Analysts recommend Eli Lilly and Company to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Eli Lilly and Company stock has an average upside potential 2026 of
0.56%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion $ | 45.04 | 63.16 |
| 32.00% | 40.23% | |
| EBITDA Margin | 41.75% | 43.69% |
| 20.21% | 4.64% | |
| Net Margin | 23.51% | 36.00% |
| 53.10% | 53.12% |
31 Analysts have issued a sales forecast Eli Lilly and Company 2025 . The average Eli Lilly and Company sales estimate is
This results in the following potential growth metrics:
20 Analysts have issued an Eli Lilly and Company EBITDA forecast 2025. The average Eli Lilly and Company EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 Eli Lilly and Company Analysts have issued a net profit forecast 2025. The average Eli Lilly and Company net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | 11.71 | 24.04 |
| 101.90% | 105.29% | |
| P/E | 42.03 | |
| EV/Sales | 15.64 |
32 Analysts have issued a Eli Lilly and Company forecast for earnings per share. The average Eli Lilly and Company EPS is
This results in the following potential growth metrics and future valuations:
Eli Lilly and Company...
Current Eli Lilly and Company Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BMO Capital |
Locked
➜
Locked
|
Locked | Dec 04 2025 |
| Bernstein |
Locked
➜
Locked
|
Locked | Nov 24 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Nov 24 2025 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Nov 19 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Nov 18 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Nov 13 2025 |
| Citigroup |
Locked
➜
Locked
|
Locked | Nov 12 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
BMO Capital:
Locked
➜
Locked
|
Dec 04 2025 |
|
Locked
Bernstein:
Locked
➜
Locked
|
Nov 24 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Nov 24 2025 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Nov 19 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Nov 18 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Nov 13 2025 |
|
Locked
Citigroup:
Locked
➜
Locked
|
Nov 12 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
